OPDIVO Qvantig Dosing and Administration Video

To prevent medication errors, check the vial labels to ensure that the drug being prepared and administered is OPDIVO Qvantig for subcutaneous use and NOT intravenous nivolumab. Do NOT administer OPDIVO Qvantig intravenously. OPDIVO Qvantig should be administered by a healthcare professional.
Each OPDIVO Qvantig vial is for one-time use only. It is a ready-to-use solution for injection. It should not be diluted.
Visually inspect for particulate matter and discoloration prior to administration. OPDIVO Qvantig is a clear to opalescent, colorless to yellow solution. Discard if the solution is discolored or contains extraneous particulate matter other than a few translucent-to-white particles. Do not shake.
No incompatibilities were observed between OPDIVO Qvantig and polypropylene and polycarbonate syringes, or between OPDIVO Qvantig and polyethylene, polyurethane, polyvinyl chloride, and fluorinated ethylene propylene subcutaneous administration sets.
A syringe and a transfer needle are needed to withdraw OPDIVO Qvantig solution from the vial. OPDIVO Qvantig may be injected subcutaneously using a 23G-25G (3/8”-5/8”) hypodermic injection needle or subcutaneous administration set (eg., winged/butterfly).
Select the appropriate syringe label provided in the carton that matches the prescribed dose and apply to the prepared syringe.
Discard partially used or empty vials of OPDIVO Qvantig.
If the dose is not to be used immediately, attach a tip cap to the syringe prior to storage. To avoid clogging of the hypodermic injection needle, attach a 23G-25G (3/8”-5/8”) hypodermic injection needle to the syringe immediately prior to administration.
Once withdrawn into the syringe, OPDIVO Qvantig should be used immediately. If not used immediately, store the syringe:
Visually inspect drug product solution for particulate matter and discoloration prior to administration. OPDIVO is a clear to opalescent, colorless to pale-yellow solution. Discard the vial if the solution is cloudy, is discolored, or contains extraneous particulate matter other than a few translucent-to-white, proteinaceous particles. Do not shake the vial.
OPDIVO
Visually inspect drug product solution for particulate matter and discoloration prior to administration. OPDIVO is a clear to opalescent, colorless to pale-yellow solution. Discard the vial if the solution is cloudy, is discolored, or contains extraneous particulate matter other than a few translucent-to-white, proteinaceous particles. Do not shake the vial.
YERVOY
When administered in combination with OPDIVO, infuse OPDIVO first followed by YERVOY on the same day. When administered with OPDIVO and platinum-doublet chemotherapy, infuse OPDIVO first followed by YERVOY and then platinum-doublet chemotherapy on the same day. Use separate infusion bags and filters for each infusion.
Refer to the respective prescribing information for each therapeutic agent administered in combination with OPDIVO for the recommended preparation and administration information, as appropriate.
IV=intravenous.
See recommended dosing modifications for immune-mediated adverse reactions with OPDIVO, YERVOY, or OPDIVO Qvantig.
Find dosing information about intravenous OPDIVO and subcutaneous injection OPDIVO Qvantig to get patients started on therapy.
A guide to dosing intravenous OPDIVO and subcutaneous injection OPDIVO Qvantig across indications.
References: